What is Wedbush’s Forecast for RARE FY2027 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Investment analysts at Wedbush increased their FY2027 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biopharmaceutical company will earn $1.05 per share for the year, up from their previous estimate of $1.04. Wedbush currently has a “Neutral” rating and a $48.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2028 earnings at $1.92 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.23) EPS.

RARE has been the subject of several other research reports. Piper Sandler lifted their price target on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. Wells Fargo & Company increased their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $92.43.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $44.85 on Friday. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37. The company’s 50-day moving average is $44.63 and its 200-day moving average is $49.59.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the company. Algert Global LLC boosted its position in Ultragenyx Pharmaceutical by 46.9% during the third quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock worth $4,105,000 after purchasing an additional 23,580 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $17,468,000. Bamco Inc. NY bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $2,666,000. Clearline Capital LP purchased a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth about $1,355,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after buying an additional 76,150 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Activity

In other news, CEO Emil D. Kakkis sold 8,273 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total transaction of $413,650.00. Following the transaction, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. This represents a 0.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.